与免疫性血小板减少症中糖皮质激素治疗反应相关的单核苷酸多态性:一项系统综述与荟萃分析。
完整摘要 · 中文译文
糖皮质激素(GCs)是免疫性血小板减少症(ITP)的标准初始治疗;然而,部分患者会出现治疗失败。遗传变异在区分GC应答者与无应答者中的作用仍不明确。我们对儿童和成人ITP的观察性研究进行了系统综述和荟萃分析,检索了截至2026年7月14日的PubMed、Embase、Scopus和Web of Science数据库,纳入报告了基因型特异性一线GC应答的研究。符合条件且报告了按基因型分层结局的单核苷酸多态性(SNP)研究被汇总以估计比值比(OR)及其95%置信区间(95% CI)。研究质量采用乔安娜布里格斯研究所(JBI)清单进行评估,证据确定性采用推荐分级的评估、制定与评价(GRADE)框架进行评级。45项研究(n = 6158)符合纳入标准,其中21项被纳入荟萃分析。IL-10 rs1800871和rs1800872与较高的GC无应答几率相关,分别增加2.8倍和3.2倍(rs1800871:OR 2.77,95% CI 1.54-4.96;rs1800872:OR 3.18,95% CI 1.77-5.70;均P < 0.001;I2 = 0%),DNAM1 rs763361也与无应答相关(OR 2.00,95% CI 1.05-3.80;P = 0.03;I2 = 27.5%),以上结果均在隐性模型下观察到。此外,TNF-α rs1800629在杂合子模型下与GC无应答相关(OR 3.89,95% CI 1.20-12.61;P = 0.02;I² = 0%)。其他所研究的基因多态性与治疗的相关性不一致或不存在。 应答,并被评定为低或极低确定性。IL-10 rs1800871/rs1800872 和 DNAM1 rs763361 成为关联最为一致的变异,得到中等确定性证据的支持。然而,这些变异具有产生假说的性质,尚未准备用于临床。在考虑任何临床应用之前,需要在更大规模、前瞻性以及种族多样化的队列中进行验证。
完整摘要 · 英文原文
Glucocorticoids (GCs) are the standard initial treatment for immune thrombocytopenia (ITP); however, some patients experience treatment failure. The role of genetic variants in distinguishing GC responders from non-responders remains unclear. We conducted a systematic review and meta-analysis of observational studies in pediatric and adult ITP, identified in PubMed, Embase, Scopus, and Web of Science up to July 14, 2026, that reported genotype-specific first-line GC responses. Eligible single-nucleotide polymorphism (SNP) studies with genotype-stratified outcomes were pooled to estimate odds ratios (OR) with 95% confidence intervals (95% CI). Study quality was assessed using the Joanna Briggs Institute (JBI) checklist, and the certainty of the evidence was rated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Forty-five studies (n = 6158) met the inclusion criteria, and 21 were included in meta-analyses. IL-10 rs1800871 and rs1800872 were associated with higher odds of GC non-response, with 2.8-fold and 3.2-fold increases, respectively (rs1800871: OR 2.77, 95% CI 1.54-4.96; rs1800872: OR 3.18, 95% CI 1.77-5.70; both P < 0.001; I2 = 0%), and DNAM1 rs763361 was also associated with non-response (OR 2.00, 95% CI 1.05-3.80; P = 0.03; I2 = 27.5%), all of which were observed under the recessive model. Moreover, TNF-α rs1800629 was associated with GC non-response under the heterozygous model (OR 3.89, 95% CI 1.20-12.61; P = 0.02; I² = 0%). Other investigated polymorphisms demonstrated inconsistent or absent associations with treatment response and were rated as low or very low certainty. IL-10 rs1800871/rs1800872 and DNAM1 rs763361 emerged as the most consistently associated variants, supported by moderate-certainty evidence. However, these variants are hypothesis-generating and are not yet ready for clinical use. Validation in larger, prospective, and ethnically diverse cohorts is needed before any clinical application can be considered.